ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
(Exact name of registrant as specified in its charter) |
(State or Other Jurisdiction of Incorporation or Organization) | (Commission File Number) | (I.R.S. Employer Identification No.) | ||||||||||||
(Address of Principal Executive Offices) | (Zip Code) |
Title of Each Class | Trading Symbol(s) | Name of Each Exchange on Which Registered | ||||||
Item 1. | |||||||||||
Item 1A. | |||||||||||
Item 1B. | |||||||||||
Item 1C. | |||||||||||
Item 2. | |||||||||||
Item 3. | |||||||||||
Item 4. | |||||||||||
Item 5. | |||||||||||
Item 6. | |||||||||||
Item 7. | |||||||||||
Item 7A. | |||||||||||
Item 8. | |||||||||||
Item 9. | |||||||||||
Item 9A. | |||||||||||
Item 9B. | |||||||||||
Item 9C. | |||||||||||
Item 10. | |||||||||||
Item 11. | |||||||||||
Item 12. | |||||||||||
Item 13. | |||||||||||
Item 14. | |||||||||||
Item 15. | |||||||||||
Item 16. |
Total Square Feet | ||||||||||||||||||||
Location | Number of Facilities | Owned | Leased | |||||||||||||||||
USA | ||||||||||||||||||||
Arizona | 1 | — | 46,100 | |||||||||||||||||
California | 2 | 157,500 | 186,100 | |||||||||||||||||
Georgia | 1 | — | 262,600 | |||||||||||||||||
Illinois | 4 | 590,500 | 286,800 | |||||||||||||||||
North Carolina | 5 | 392,200 | 415,500 | |||||||||||||||||
Ohio | 1 | 42,500 | — | |||||||||||||||||
Pennsylvania | 4 | 119,000 | 216,000 | |||||||||||||||||
Texas | 3 | 175,000 | 284,200 | |||||||||||||||||
International | ||||||||||||||||||||
Canada | 4 | 72,600 | 195,600 | |||||||||||||||||
Mexico | 1 | 106,100 | — | |||||||||||||||||
United Arab Emirates | 1 | — | 6,000 |
Name | Age | Position(s) | In Current Position(s) since | |||||||||||||||||
Todd A. Adams | 54 | Chairman of the Board and Chief Executive Officer | 2020 | |||||||||||||||||
David J. Pauli | 42 | Chief Financial Officer | 2024 | |||||||||||||||||
Sudhanshu Chhabra | 58 | Vice President, Zurn Elkay Business Systems | 2018 | |||||||||||||||||
Jeffrey J. LaValle | 46 | Vice President, General Counsel and Corporate Secretary | 2022 | |||||||||||||||||
Mark W. Peterson | 53 | Chief Administrative Officer | 2024 | |||||||||||||||||
Jeffrey A. Schoon | 43 | President | 2024 | |||||||||||||||||
Michael D. Troutman | 58 | Chief Information Officer | 2007 |
ISSUER PURCHASES OF EQUITY SECURITIES | |||||||||||||||||||||||
Total Number of Shares Purchased | Average Price Paid per Share | Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs (1) | Maximum Approximate Dollar Value that may yet be Purchased Under the Plans or Programs (1) | ||||||||||||||||||||
Period | |||||||||||||||||||||||
October 1 - October 31, 2024 | 227,728 | $ | 36.49 | 227,728 | $ | 252,236,711 | |||||||||||||||||
November 1 - November 30, 2024 | 144,698 | $ | 39.25 | 144,698 | $ | 246,554,377 | |||||||||||||||||
December 1 - December 31, 2024 | 161,142 | $ | 39.26 | 161,142 | $ | 240,224,683 | |||||||||||||||||
Total/Average | 533,568 | $ | 38.08 | 533,568 |
3/31/2020 | 12/31/2020 | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2024 | |||||||||||||||
Zurn Elkay Water Solutions Corporation (1) | $ | 100 | $ | 174 | $ | 327 | $ | 190 | $ | 264 | $ | 335 | ||||||||
S&P 500 Index | $ | 100 | $ | 145 | $ | 184 | $ | 149 | $ | 185 | $ | 228 | ||||||||
S&P 1500 Industrials Index | $ | 100 | $ | 152 | $ | 184 | $ | 169 | $ | 200 | $ | 231 |
Year Ended | |||||||||||||||||
(1) | (1) | (2) | |||||||||||||||
December 31, 2024 | December 31, 2023 | December 31, 2022 | |||||||||||||||
Selling, general and administrative income | (0.7) | (8.4) | (2.9) | ||||||||||||||
Income from discontinued operations before income tax | 0.7 | 8.4 | 2.9 | ||||||||||||||
Income tax benefit | 0.6 | 0.1 | 1.8 | ||||||||||||||
Income from discontinued operations, net of tax | $ | 1.3 | $ | 8.5 | $ | 4.7 |
Year Ended | |||||||||||||||||||||||
December 31, 2024 | December 31, 2023 | Change | % Change | ||||||||||||||||||||
Net sales | $ | 1,566.5 | $ | 1,530.5 | $ | 36.0 | 2.4 | % |
Year Ended | |||||||||||||||||||||||
December 31, 2024 | December 31, 2023 | Change | % Change | ||||||||||||||||||||
Income from operations | $ | 244.6 | $ | 191.4 | $ | 53.2 | 27.8 | % | |||||||||||||||
% of net sales | 15.6 | % | 12.5 | % | 3.1 | % |
(in millions) | Year Ended December 31, 2024 | |||||||
Net income | $ | 160.2 | ||||||
Income from discontinued operations, net of tax (1) | (1.3) | |||||||
Provision for income taxes | 48.1 | |||||||
Actuarial gain on pension and other postretirement benefit obligations | (1.4) | |||||||
Other expense, net (2) | 5.9 | |||||||
Interest expense, net | 33.1 | |||||||
Depreciation and amortization | 88.3 | |||||||
EBITDA | 332.9 | |||||||
Adjustments to EBITDA | ||||||||
Restructuring and other similar charges (3) | 13.5 | |||||||
Stock-based compensation expense | 37.9 | |||||||
LIFO (4) | 5.5 | |||||||
Other, net (5) | 0.6 | |||||||
Subtotal of adjustments to EBITDA | 57.5 | |||||||
Adjusted EBITDA | 390.4 | |||||||
Consolidated indebtedness (6) | $ | 336.4 | ||||||
Net First Lien Leverage Ratio (7) | 0.86 |
Total Debt at December 31, 2024 | Current Maturities of Long-Term Debt | Long-term Portion | ||||||||||||||||||
Term loan (1) | $ | 475.0 | $ | — | $ | 475.0 | ||||||||||||||
Finance leases | 20.6 | 0.8 | 19.8 | |||||||||||||||||
Total | $ | 495.6 | $ | 0.8 | $ | 494.8 |
Pension Benefit Obligation | |||||
Description of the Matter | At December 31, 2024, the Company’s projected benefit obligation related to its pension plans was $ | ||||
How We Addressed the Matter in Our Audit | We obtained an understanding, evaluated the design, and tested the operating effectiveness of controls over the Company’s valuation of the projected benefit obligation. For example, we tested the Company’s controls over management’s review of the significant assumptions utilized in the valuation, including discount and mortality rates. To test the projected benefit obligation, we performed audit procedures that included, among others, evaluating the methodology used, the significant actuarial assumptions described above, and the underlying data used by the Company. We evaluated the change in the projected benefit obligation from the prior year due to the change in service cost, interest cost, actuarial gains and losses, benefit payments, and other activities. In addition, we involved our actuary to assist in evaluating management’s methodology for selecting the appropriate discount rates that reflect the maturity and duration of the expected benefit payments and applying those discount rates to the benefit payments used to measure the projected benefit obligation. To evaluate the mortality rates, we assessed whether the information is consistent with publicly available information, and whether any adjustments for entity-specific factors were applied. |
December 31, 2024 | December 31, 2023 | |||||||||||||
Assets | ||||||||||||||
Current assets: | ||||||||||||||
Cash and cash equivalents | $ | $ | ||||||||||||
Receivables, net | ||||||||||||||
Inventories, net | ||||||||||||||
Income taxes receivable | ||||||||||||||
Other current assets | ||||||||||||||
Total current assets | ||||||||||||||
Property, plant and equipment, net | ||||||||||||||
Intangible assets, net | ||||||||||||||
Goodwill | ||||||||||||||
Other assets | ||||||||||||||
Total assets | $ | $ | ||||||||||||
Liabilities and stockholders' equity | ||||||||||||||
Current liabilities: | ||||||||||||||
Current maturities of debt | $ | $ | ||||||||||||
Trade payables | ||||||||||||||
Compensation and benefits | ||||||||||||||
Current portion of pension and other postretirement benefit obligations | ||||||||||||||
Other current liabilities | ||||||||||||||
Total current liabilities | ||||||||||||||
Long-term debt | ||||||||||||||
Pension and other postretirement benefit obligations | ||||||||||||||
Deferred income taxes | ||||||||||||||
Operating lease liability | ||||||||||||||
Other liabilities | ||||||||||||||
Total liabilities | ||||||||||||||
Stockholders' equity: | ||||||||||||||
Common stock, $ | ||||||||||||||
Additional paid-in capital | ||||||||||||||
Retained deficit | ( | ( | ||||||||||||
Accumulated other comprehensive loss | ( | ( | ||||||||||||
Total stockholders' equity | ||||||||||||||
Total liabilities and stockholders' equity | $ | $ |
Year Ended | ||||||||||||||||||||
December 31, 2024 | December 31, 2023 | December 31, 2022 | ||||||||||||||||||
Net sales | $ | $ | $ | |||||||||||||||||
Cost of sales | ||||||||||||||||||||
Gross profit | ||||||||||||||||||||
Selling, general and administrative expenses | ||||||||||||||||||||
Restructuring and other similar charges | ||||||||||||||||||||
Loss on divestiture of asbestos liabilities and certain assets | ||||||||||||||||||||
Amortization of intangible assets | ||||||||||||||||||||
Income from operations | ||||||||||||||||||||
Non-operating expense: | ||||||||||||||||||||
Interest expense, net | ( | ( | ( | |||||||||||||||||
Loss on the extinguishment of debt | ( | |||||||||||||||||||
Actuarial gain on pension and other postretirement benefit obligations | ||||||||||||||||||||
Other income (expense), net | ( | ( | ||||||||||||||||||
Income before income taxes | ||||||||||||||||||||
Provision for income taxes | ( | ( | ( | |||||||||||||||||
Net income from continuing operations | ||||||||||||||||||||
Income from discontinued operations, net of tax | ||||||||||||||||||||
Net income | $ | $ | $ | |||||||||||||||||
Basic net income per share: | ||||||||||||||||||||
Continuing operations | $ | $ | $ | |||||||||||||||||
Discontinued operations | $ | $ | $ | |||||||||||||||||
Net income | $ | $ | $ | |||||||||||||||||
Diluted net income per share: | ||||||||||||||||||||
Continuing operations | $ | $ | $ | |||||||||||||||||
Discontinued operations | $ | $ | $ | |||||||||||||||||
Net income | $ | $ | $ | |||||||||||||||||
Weighted-average number of common shares outstanding (in thousands): | ||||||||||||||||||||
Basic | ||||||||||||||||||||
Effect of dilutive equity awards | ||||||||||||||||||||
Diluted |
Year Ended | ||||||||||||||||||||
December 31, 2024 | December 31, 2023 | December 31, 2022 | ||||||||||||||||||
Net income | $ | $ | $ | |||||||||||||||||
Other comprehensive income (loss): | ||||||||||||||||||||
Foreign currency translation and other adjustments | ( | ( | ||||||||||||||||||
Change in pension and other postretirement defined benefit plans, net of tax | ||||||||||||||||||||
Other comprehensive income (loss), net of tax | ( | ( | ||||||||||||||||||
Total comprehensive income | $ | $ | $ |
Common Stock | Additional Paid-In Capital | Retained (Deficit) Earnings | Accumulated Other Comprehensive (Loss) Income | Total Stockholders’ Equity | |||||||||||||||||||||||||
Balance at December 31, 2021 | $ | $ | $ | ( | $ | ( | $ | ||||||||||||||||||||||
Net income | $ | — | $ | — | $ | $ | — | $ | |||||||||||||||||||||
Foreign currency translation and other adjustments | — | — | — | ( | ( | ||||||||||||||||||||||||
Change in pension and other postretirement defined benefit plans, net of $ | — | — | — | ||||||||||||||||||||||||||
Total comprehensive income (loss) | — | — | ( | ||||||||||||||||||||||||||
Stock-based compensation expense | — | — | — | ||||||||||||||||||||||||||
Proceeds from exercise of stock options | — | — | — | ||||||||||||||||||||||||||
Taxes withheld and paid on employees' share-based payment awards | — | ( | — | — | ( | ||||||||||||||||||||||||
Repurchase of common stock (1) | — | — | ( | — | ( | ||||||||||||||||||||||||
Proceeds associated with divestiture of discontinued operations | — | — | — | ||||||||||||||||||||||||||
Elkay Merger (2) | — | — | |||||||||||||||||||||||||||
Common stock dividends ($ | — | ( | — | — | ( | ||||||||||||||||||||||||
Balance at December 31, 2022 | $ | $ | $ | ( | $ | ( | $ | ||||||||||||||||||||||
Net income | $ | — | $ | — | $ | $ | — | $ | |||||||||||||||||||||
Foreign currency translation and other adjustments | — | — | — | ||||||||||||||||||||||||||
Change in pension and other postretirement defined benefit plans, net of $ | — | — | — | ||||||||||||||||||||||||||
Total comprehensive income | — | — | |||||||||||||||||||||||||||
Stock-based compensation expense | — | — | — | ||||||||||||||||||||||||||
Proceeds from exercise of stock options | — | — | — | ||||||||||||||||||||||||||
Taxes withheld and paid on employees' share-based payment awards | — | ( | — | — | ( | ||||||||||||||||||||||||
Repurchase of common stock (1) | ( | — | ( | — | ( | ||||||||||||||||||||||||
Elkay Merger (2) | — | ( | — | — | ( | ||||||||||||||||||||||||
Common stock dividends ($ | — | ( | — | — | ( | ||||||||||||||||||||||||
Balance at December 31, 2023 | $ | $ | $ | ( | $ | ( | $ | ||||||||||||||||||||||
Net income | $ | — | $ | — | $ | $ | — | $ | |||||||||||||||||||||
Foreign currency translation and other adjustments | — | — | — | ( | ( | ||||||||||||||||||||||||
Change in pension and other postretirement defined benefit plans, net of $ | — | — | — | ||||||||||||||||||||||||||
Total comprehensive income | — | — | ( | ||||||||||||||||||||||||||
Stock-based compensation expense | — | — | — | ||||||||||||||||||||||||||
Proceeds from exercise of stock options and ESPP contributions | — | — | — | ||||||||||||||||||||||||||
Taxes withheld and paid on employees' share-based payment awards | — | ( | — | — | ( | ||||||||||||||||||||||||
Repurchase of common stock (1) | — | — | ( | — | ( | ||||||||||||||||||||||||
Common stock dividends ($ | — | ( | — | — | ( | ||||||||||||||||||||||||
Balance at December 31, 2024 | $ | $ | $ | ( | $ | ( | $ |
Year Ended | ||||||||||||||||||||
December 31, 2024 | December 31, 2023 | December 31, 2022 | ||||||||||||||||||
Operating activities | ||||||||||||||||||||
Net income | $ | $ | $ | |||||||||||||||||
Adjustments to reconcile net income to cash provided by operating activities: | ||||||||||||||||||||
Depreciation | ||||||||||||||||||||
Amortization of intangible assets | ||||||||||||||||||||
Non-cash restructuring charges | ||||||||||||||||||||
Loss on divestiture of asbestos liabilities and certain assets | ||||||||||||||||||||
Divestiture of asbestos liabilities and certain assets | ( | |||||||||||||||||||
Loss (gain) on dispositions of long-lived assets | ( | |||||||||||||||||||
Deferred income taxes | ( | ( | ||||||||||||||||||
Other non-cash expenses | ||||||||||||||||||||
Actuarial gain on pension and other postretirement benefit obligations | ( | ( | ( | |||||||||||||||||
Loss on the extinguishment of debt | ||||||||||||||||||||
Stock-based compensation expense | ||||||||||||||||||||
Changes in operating assets and liabilities: | ||||||||||||||||||||
Receivables, net | ||||||||||||||||||||
Inventories, net | ( | |||||||||||||||||||
Other assets | ||||||||||||||||||||
Accounts payable | ( | ( | ||||||||||||||||||
Accruals and other | ( | ( | ||||||||||||||||||
Cash provided by operating activities | ||||||||||||||||||||
Investing activities | ||||||||||||||||||||
Expenditures for property, plant and equipment | ( | ( | ( | |||||||||||||||||
Acquisitions, net of cash acquired | ( | |||||||||||||||||||
Proceeds from dispositions of long-lived assets | ||||||||||||||||||||
Proceeds from insurance claims | ||||||||||||||||||||
Proceeds associated with divestiture of discontinued operations | ||||||||||||||||||||
Cash used for investing activities | ( | ( | ( | |||||||||||||||||
Financing activities | ||||||||||||||||||||
Proceeds from borrowings of debt | ||||||||||||||||||||
Repayments of debt | ( | ( | ( | |||||||||||||||||
Proceeds from exercise of stock options and ESPP contributions | ||||||||||||||||||||
Taxes withheld and paid on employees' share-based payment awards | ( | ( | ( | |||||||||||||||||
Repurchase of common stock | ( | ( | ( | |||||||||||||||||
Payment of common stock dividends | ( | ( | ( | |||||||||||||||||
Cash used for financing activities | ( | ( | ( | |||||||||||||||||
Effect of exchange rate changes on cash, cash equivalents and restricted cash | ( | ( | ||||||||||||||||||
Increase in cash, cash equivalents and restricted cash | ||||||||||||||||||||
Cash, cash equivalents and restricted cash at beginning of period (1) | ||||||||||||||||||||
Cash, cash equivalents and restricted cash at end of period (1) | $ | $ | $ |
Year Ended | |||||||||||||||||
December 31, 2024 | December 31, 2023 | December 31, 2022 | |||||||||||||||
Balance at beginning of period | $ | $ | $ | ||||||||||||||
Acquired obligations | |||||||||||||||||
Charged to operations | |||||||||||||||||
Claims settled | ( | ( | ( | ||||||||||||||
Balance at end of period | $ | $ | $ |
Foreign Currency Translation and Other Adjustments | Pension and Other Postretirement Plans | Total | ||||||||||||||||||
Balance at December 31, 2021 | $ | ( | $ | ( | $ | ( | ||||||||||||||
Other comprehensive (loss) income before reclassifications | $ | ( | $ | $ | ( | |||||||||||||||
Balance at December 31, 2022 | $ | ( | $ | $ | ( | |||||||||||||||
Other comprehensive income before reclassifications | $ | $ | $ | |||||||||||||||||
Balance at December 31, 2023 | $ | ( | $ | $ | ( | |||||||||||||||
Other comprehensive (loss) income before reclassifications | $ | ( | $ | $ | ( | |||||||||||||||
Balance at December 31, 2024 | $ | ( | $ | $ | ( |
As Reported June 30, 2023 | ||||||||
Assets acquired: | ||||||||
Receivables, net | $ | |||||||
Inventories | ||||||||
Other current assets | ||||||||
Property, plant and equipment, net | ||||||||
Intangible assets, net | ||||||||
Goodwill | ||||||||
Other assets | ||||||||
Total assets acquired | $ | |||||||
Liabilities assumed: | ||||||||
Trade payables | $ | |||||||
Compensation and benefits | ||||||||
Current portion of pension and other postretirement benefit obligations | ||||||||
Other current liabilities | ||||||||
Operating lease liability | ||||||||
Pension and other postretirement benefit obligations | ||||||||
Deferred income taxes | ||||||||
Other liabilities | ||||||||
Total liabilities assumed | ||||||||
Total purchase price | $ |
Year Ended | |||||
December 31, 2022 | |||||
Net sales | $ | ||||
Net income from continuing operations | $ | ||||
Earnings per share from continuing operations | |||||
Basic | $ | ||||
Assuming dilution | $ |
Year Ended | |||||||||||||||||
(1) | (1) | (2) | |||||||||||||||
December 31, 2024 | December 31, 2023 | December 31, 2022 | |||||||||||||||
Selling, general and administrative income | ( | ( | ( | ||||||||||||||
Income from discontinued operations before income tax | |||||||||||||||||
Income tax benefit | |||||||||||||||||
Income from discontinued operations, net of tax | $ | $ | $ |
Year Ended | ||||||||
December 31, 2022 | ||||||||
Net payments from divestiture of discontinued operations | $ | |||||||
Year Ended | ||||||||||||||||||||
December 31, 2024 | December 31, 2023 | December 31, 2022 | ||||||||||||||||||
Employee termination benefits | $ | $ | $ | |||||||||||||||||
Asset impairment charges | ||||||||||||||||||||
Contract termination and other associated costs | ||||||||||||||||||||
Total restructuring and other similar charges | $ | $ | $ | |||||||||||||||||
Restructuring Costs To-date (Period from April 1, 2011 to December 31, 2024) | Restructuring Costs To-date (Period from April 1, 2011 to December 31, 2024) | |||||||||||||||||||
Employee termination benefits | $ | |||||||||||||||||||
Asset impairment charges | ||||||||||||||||||||
Contract termination and other associated costs | ||||||||||||||||||||
Total restructuring and other similar charges | $ |
Employee termination benefits | Asset impairment charges | Contract termination and other associated costs | Total | |||||||||||||||||||||||
Accrued restructuring costs, December 31, 2022 | $ | $ | $ | $ | ||||||||||||||||||||||
Charges | ||||||||||||||||||||||||||
Cash payments | ( | ( | ( | |||||||||||||||||||||||
Non-cash charges | ( | ( | ||||||||||||||||||||||||
Accrued restructuring costs, December 31, 2023 (1) | $ | $ | $ | $ | ||||||||||||||||||||||
Charges | ||||||||||||||||||||||||||
Cash payments | ( | ( | ( | |||||||||||||||||||||||
Non-cash charges | ( | ( | ||||||||||||||||||||||||
Accrued restructuring costs, December 31, 2024 (1) | $ | $ | $ | $ |
Year Ended | ||||||||||||||||||||
Customer Type | December 31, 2024 | December 31, 2023 | December 31, 2022 | |||||||||||||||||
Institutional | $ | $ | $ | |||||||||||||||||
Commercial | ||||||||||||||||||||
All other | ||||||||||||||||||||
Total | $ | $ | $ |
Year Ended | ||||||||||||||||||||
Geography | December 31, 2024 | December 31, 2023 | December 31, 2022 | |||||||||||||||||
United States | $ | $ | $ | |||||||||||||||||
Canada | ||||||||||||||||||||
Rest of world | ||||||||||||||||||||
Total | $ | $ | $ |
December 31, 2024 | December 31, 2023 | ||||||||||
Finished goods | $ | $ | |||||||||
Work in progress | |||||||||||
Raw materials | |||||||||||
Inventories at First-in, First-Out ("FIFO") cost | |||||||||||
Adjustment to state inventories at Last-in, First-Out ("LIFO") cost | ( | ( | |||||||||
$ | $ |
December 31, 2024 | December 31, 2023 | ||||||||||
Land | $ | $ | |||||||||
Buildings and improvements | |||||||||||
Machinery and equipment | |||||||||||
Computer hardware and software | |||||||||||
Construction in-progress | |||||||||||
Less accumulated depreciation | ( | ( | |||||||||
$ | $ |
Net carrying amount as of December 31, 2022 | $ | |||||||
Purchase accounting adjustments (1) | ||||||||
Net carrying amount as of December 31, 2023 | $ | |||||||
Currency translation adjustments | ( | |||||||
Net carrying amount as of December 31, 2024 | $ |
December 31, 2024 | |||||||||||||||||||||||
Weighted Average Useful Life | Gross Carrying Amount | Accumulated Amortization | Net Carrying Amount | ||||||||||||||||||||
Intangible assets subject to amortization: | |||||||||||||||||||||||
Patents | $ | $ | ( | $ | |||||||||||||||||||
Customer relationships (including distribution network) | ( | ||||||||||||||||||||||
Tradenames | ( | ||||||||||||||||||||||
Intangible assets not subject to amortization - trademarks and tradenames | — | ||||||||||||||||||||||
Total intangible assets, net | $ | $ | ( | $ | |||||||||||||||||||
December 31, 2023 | |||||||||||||||||||||||
Weighted Average Useful Life | Gross Carrying Amount | Accumulated Amortization | Net Carrying Amount | ||||||||||||||||||||
Intangible assets subject to amortization: | |||||||||||||||||||||||
Patents | $ | $ | ( | $ | |||||||||||||||||||
Customer relationships (including distribution network) | ( | ||||||||||||||||||||||
Tradenames | ( | ||||||||||||||||||||||
Intangible assets not subject to amortization - trademarks and tradenames | — | ||||||||||||||||||||||
Total intangible assets, net | $ | $ | ( | $ |
December 31, 2024 | December 31, 2023 | ||||||||||
Commissions | $ | $ | |||||||||
Income taxes payable | |||||||||||
Professional fees | |||||||||||
Product warranty (2) | |||||||||||
Restructuring and other similar charges (3) | |||||||||||
Risk management (4) | |||||||||||
Sales rebates | |||||||||||
Tax indemnities | |||||||||||
Taxes, other than income taxes | |||||||||||
Other | |||||||||||
$ | $ |
December 31, 2024 | December 31, 2023 | |||||||||||||
Term loan (1) | $ | $ | ||||||||||||
Finance leases (2) | ||||||||||||||
Total | ||||||||||||||
Less current maturities | ||||||||||||||
Long-term debt | $ | $ |
Years ending December 31: | |||||
2025 | $ | ||||
2026 | |||||
2027 | |||||
2028 | |||||
2029 | |||||
Thereafter | |||||
$ |
Leases | Classification | December 31, 2024 | December 31, 2023 | |||||||||||||||||
Assets: | ||||||||||||||||||||
Operating ROU assets | $ | $ | ||||||||||||||||||
Finance ROU assets | ||||||||||||||||||||
Total ROU assets | $ | $ | ||||||||||||||||||
Liabilities: | ||||||||||||||||||||
Current | ||||||||||||||||||||
Operating | $ | $ | ||||||||||||||||||
Finance | ||||||||||||||||||||
Non-current | ||||||||||||||||||||
Operating | Operating lease liability | |||||||||||||||||||
Finance | ||||||||||||||||||||
Total lease liabilities | $ | $ |
Year Ended | ||||||||||||||||||||
December 31, 2024 | December 31, 2023 | December 31, 2022 | ||||||||||||||||||
Operating lease expenses (1) | $ | $ | $ | |||||||||||||||||
Finance lease expenses: | ||||||||||||||||||||
Depreciation of finance ROU assets (1) | ||||||||||||||||||||
Interest on lease liabilities (2) | ||||||||||||||||||||
Total finance lease expense | ||||||||||||||||||||
Variable and short-term lease expense (1) | ||||||||||||||||||||
Total lease expense | $ | $ | $ |
Years ending December 31, | Operating Leases | Finance Leases | ||||||||||||
2025 | $ | $ | ||||||||||||
2026 | ||||||||||||||
2027 | ||||||||||||||
2028 | ||||||||||||||
2029 | ||||||||||||||
Thereafter | ||||||||||||||
Total future minimum lease payments | ||||||||||||||
Less: Imputed interest | ( | ( | ||||||||||||
Total lease liabilities | $ | $ |
Year Ended | ||||||||||||||||||||
Lease Term and Discount Rate | December 31, 2024 | December 31, 2023 | December 31, 2022 | |||||||||||||||||
Weighted-average remaining lease terms (years): | ||||||||||||||||||||
Operating leases | ||||||||||||||||||||
Finance leases | ||||||||||||||||||||
Weighted-average discount rate: | ||||||||||||||||||||
Operating leases | % | % | % | |||||||||||||||||
Finance leases | % | % | % |
Year Ended | ||||||||||||||||||||
December 31, 2024 | December 31, 2023 | December 31, 2022 | ||||||||||||||||||
Operating cash flows from operating leases | $ | $ | $ | |||||||||||||||||
Operating cash flows from finance leases | ||||||||||||||||||||
Financing cash flows from finance leases |
Year Ended | ||||||||||||||||||||
December 31, 2024 | December 31, 2023 | December 31, 2022 | ||||||||||||||||||
Operating leases | $ | $ | $ | |||||||||||||||||
Finance leases | ( |
Year Ended | ||||||||||||||||||||
December 31, 2024 | December 31, 2023 | December 31, 2022 | ||||||||||||||||||
Expected option term (in years) | ||||||||||||||||||||
Expected volatility factor | % | % | % | |||||||||||||||||
Weighted-average risk-free interest rate | % | % | % | |||||||||||||||||
Expected dividend rate | % | % | % |
Year Ended | ||||||||||||||||||||||||||||||||||||||
December 31, 2024 | December 31, 2023 | December 31, 2022 | ||||||||||||||||||||||||||||||||||||
Shares | Weighted Avg. Exercise Price | Shares | Weighted Avg. Exercise Price | Shares | Weighted Avg. Exercise Price | |||||||||||||||||||||||||||||||||
Number of shares under options: | ||||||||||||||||||||||||||||||||||||||
Outstanding at beginning of period | $ | $ | $ | |||||||||||||||||||||||||||||||||||
Granted | ||||||||||||||||||||||||||||||||||||||
Exercised (1) | ( | ( | ( | |||||||||||||||||||||||||||||||||||
Canceled/Forfeited | ( | ( | ( | |||||||||||||||||||||||||||||||||||
Outstanding at end of period (2) | $ | $ | $ | |||||||||||||||||||||||||||||||||||
Exercisable at end of period (3) | $ | $ | $ |
Shares | Weighted Avg. Exercise Price | |||||||||||||
Nonvested options at beginning of period | $ | |||||||||||||
Granted | ||||||||||||||
Vested | ( | |||||||||||||
Canceled/Forfeited | ( | |||||||||||||
Nonvested options at end of period | $ |
Year Ended | ||||||||||||||||||||||||||||||||||||||
December 31, 2024 | December 31, 2023 | December 31, 2022 | ||||||||||||||||||||||||||||||||||||
Units | Weighted Avg. Grant Date Fair Value | Units | Weighted Avg. Grant Date Fair Value | Units | Weighted Avg. Grant Date Fair Value | |||||||||||||||||||||||||||||||||
Nonvested RSUs at beginning of period | $ | $ | $ | |||||||||||||||||||||||||||||||||||
Granted | ||||||||||||||||||||||||||||||||||||||
Vested | ( | ( | ( | |||||||||||||||||||||||||||||||||||
Canceled/Forfeited | ( | ( | ( | |||||||||||||||||||||||||||||||||||
Nonvested RSUs at end of period | $ | $ | $ |
Year Ended | ||||||||||||||||||||||||||||||||||||||
December 31, 2024 | December 31, 2023 | December 31, 2022 | ||||||||||||||||||||||||||||||||||||
Units | Weighted Avg. Grant Date Fair Value | Units | Weighted Avg. Grant Date Fair Value | Units | Weighted Avg. Grant Date Fair Value | |||||||||||||||||||||||||||||||||
Nonvested PSUs at beginning of period | $ | $ | $ | |||||||||||||||||||||||||||||||||||
Granted | ||||||||||||||||||||||||||||||||||||||
Vested (1) | ( | ( | ||||||||||||||||||||||||||||||||||||
Canceled/Forfeited | ( | ( | ( | |||||||||||||||||||||||||||||||||||
Nonvested PSUs at end of period | $ | $ | $ |
Year Ended | ||||||||||||||||||||
December 31, 2024 | December 31, 2023 | December 31, 2022 | ||||||||||||||||||
Pension Benefits: | ||||||||||||||||||||
Service cost | $ | $ | $ | |||||||||||||||||
Interest cost | ||||||||||||||||||||
Expected return on plan assets | ( | ( | ( | |||||||||||||||||
Recognition of actuarial gains | ( | |||||||||||||||||||
Net periodic benefit (income) expense | $ | $ | $ | ( | ||||||||||||||||
Other Postretirement Benefits: | ||||||||||||||||||||
Interest cost | $ | $ | $ | |||||||||||||||||
Recognition of actuarial gains | ( | ( | ( | |||||||||||||||||
Net periodic benefit (income) expense | $ | ( | $ | ( | $ | ( |
Pension Benefits | Other Postretirement Benefits | |||||||||||||||||||||||||
Year Ended December 31, 2024 | Year Ended December 31, 2023 | Year Ended December 31, 2024 | Year Ended December 31, 2023 | |||||||||||||||||||||||
Benefit obligation at beginning of period | $ | ( | $ | ( | $ | ( | $ | ( | ||||||||||||||||||
Service cost | ( | ( | ||||||||||||||||||||||||
Interest cost | ( | ( | ( | ( | ||||||||||||||||||||||
Actuarial (losses) gains | ( | |||||||||||||||||||||||||
Benefits paid | ||||||||||||||||||||||||||
Plan participant contributions | ( | ( | ||||||||||||||||||||||||
Settlements | ||||||||||||||||||||||||||
Benefit obligation at end of period | $ | ( | $ | ( | $ | ( | $ | ( | ||||||||||||||||||
Plan assets at the beginning of the period | $ | $ | $ | $ | ||||||||||||||||||||||
Actual return on plan assets | ||||||||||||||||||||||||||
Contributions | ||||||||||||||||||||||||||
Benefits paid | ( | ( | ( | ( | ||||||||||||||||||||||
Settlements | ( | |||||||||||||||||||||||||
Plan assets at end of period | $ | $ | $ | $ | ||||||||||||||||||||||
Funded status of plans | $ | ( | $ | ( | $ | ( | $ | ( | ||||||||||||||||||
Net amount on Consolidated Balance Sheets consists of: | ||||||||||||||||||||||||||
Non-current assets | $ | $ | $ | $ | ||||||||||||||||||||||
Current liabilities | $ | ( | $ | ( | $ | ( | $ | ( | ||||||||||||||||||
Long-term liabilities | ( | ( | ( | ( | ||||||||||||||||||||||
Total net funded status | $ | ( | $ | ( | $ | ( | $ | ( |
As of December 31, 2024 | ||||||||||||||||||||
Pension Benefits | Other Postretirement Benefits | Total | ||||||||||||||||||
Unrecognized actuarial gain | ( | ( | ( | |||||||||||||||||
Accumulated other comprehensive income, gross | ( | ( | ( | |||||||||||||||||
Deferred income tax provision | ||||||||||||||||||||
Accumulated other comprehensive income, net | $ | ( | $ | ( | $ | ( |
As of December 31, 2023 | ||||||||||||||||||||
Pension Benefits | Other Postretirement Benefits | Total | ||||||||||||||||||
Unrecognized actuarial gain | ( | ( | ( | |||||||||||||||||
Accumulated other comprehensive income, gross | ( | ( | ( | |||||||||||||||||
Deferred income tax provision | ||||||||||||||||||||
Accumulated other comprehensive income, net | $ | ( | $ | ( | $ | ( |
Pension Benefits | Other Postretirement Benefits | |||||||||||||||||||||||||||||||||||||
December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2024 | December 31, 2023 | December 31, 2022 | |||||||||||||||||||||||||||||||||
Benefit Obligations: | ||||||||||||||||||||||||||||||||||||||
Discount rate | % | % | % | % | % | % | ||||||||||||||||||||||||||||||||
Rate of compensation increase | % | % | % | n/a | n/a | n/a | ||||||||||||||||||||||||||||||||
Net Periodic Benefit Cost: | ||||||||||||||||||||||||||||||||||||||
Discount rate | % | % | % | % | % | % | ||||||||||||||||||||||||||||||||
Rate of compensation increase | % | % | % | n/a | n/a | n/a | ||||||||||||||||||||||||||||||||
Expected return on plan assets | % | % | % | n/a | n/a | n/a |
Plan Assets | ||||||||||||||||||||||||||||||||
December 31, 2024 | December 31, 2023 | |||||||||||||||||||||||||||||||
Investment Policy (1) | Target Allocation (2) | Actual Allocation | Actual Allocation | |||||||||||||||||||||||||||||
Equity securities | - | |||||||||||||||||||||||||||||||
Debt securities (including cash and cash equivalents) | - | |||||||||||||||||||||||||||||||
December 31, 2024 | ||||||||||||||||||||||||||||||||
Quoted Prices in Active Market (Level 1) | Significant Other Observable Inputs (Level 2) | Significant Unobservable Inputs (Level 3) | Assets Measured at Net Asset Value (1) | Total | ||||||||||||||||||||||||||||
Cash and cash equivalents | $ | $ | $ | $ | $ | |||||||||||||||||||||||||||
Investment funds | ||||||||||||||||||||||||||||||||
Fixed income funds (2) | ||||||||||||||||||||||||||||||||
U.S. equity funds (3) | ||||||||||||||||||||||||||||||||
International equity funds (3) | ||||||||||||||||||||||||||||||||
Balanced funds (3) | ||||||||||||||||||||||||||||||||
Total | $ | $ | $ | $ | $ |
December 31, 2023 | ||||||||||||||||||||||||||||||||
Quoted Prices in Active Market (Level 1) | Significant Other Observable Inputs (Level 2) | Significant Unobservable Inputs (Level 3) | Assets Measured at Net Asset Value (1) | Total | ||||||||||||||||||||||||||||
Cash and cash equivalents | $ | $ | $ | $ | $ | |||||||||||||||||||||||||||
Investment funds | ||||||||||||||||||||||||||||||||
Fixed income funds (2) | ||||||||||||||||||||||||||||||||
U.S. equity funds (3) | ||||||||||||||||||||||||||||||||
International equity funds (3) | ||||||||||||||||||||||||||||||||
Balanced funds (3) | ||||||||||||||||||||||||||||||||
Total | $ | $ | $ | $ | $ |
Years Ending December 31: | Pension Benefits | Other Postretirement Benefits | ||||||||||||
2025 | $ | $ | ||||||||||||
2026 | ||||||||||||||
2027 | ||||||||||||||
2028 | ||||||||||||||
2029 | ||||||||||||||
2030 - 2034 |
Fair Value as of December 31, 2024 | ||||||||||||||||||||||||||
Quoted Prices in Active Market (Level 1) | Significant Other Observable Inputs (Level 2) | Significant Unobservable Inputs (Level 3) | Total | |||||||||||||||||||||||
Deferred compensation plan assets: | ||||||||||||||||||||||||||
Mutual funds (1) | $ | $ | $ | $ | ||||||||||||||||||||||
Corporate-owned life insurance policies (2) | ||||||||||||||||||||||||||
Total assets at fair value | $ | $ | $ | $ | ||||||||||||||||||||||
Deferred compensation liability at fair value (3): | $ | $ | $ | $ | ||||||||||||||||||||||
Fair Value as of December 31, 2023 | ||||||||||||||||||||||||||
Quoted Prices in Active Market (Level 1) | Significant Other Observable Inputs (Level 2) | Significant Unobservable Inputs (Level 3) | Total | |||||||||||||||||||||||
Deferred compensation plan assets: | ||||||||||||||||||||||||||
Mutual funds (1) | $ | $ | $ | $ | ||||||||||||||||||||||
Corporate-owned life insurance policies (2) | ||||||||||||||||||||||||||
Total assets at fair value | $ | $ | $ | $ | ||||||||||||||||||||||
Deferred compensation liability at fair value (3): | $ | $ | $ | $ |
Year Ended | ||||||||||||||||||||
December 31, 2024 | December 31, 2023 | December 31, 2022 | ||||||||||||||||||
Current: | ||||||||||||||||||||
United States | $ | $ | $ | |||||||||||||||||
Non-United States | ||||||||||||||||||||
State and local | ||||||||||||||||||||
Total current | ||||||||||||||||||||
Deferred: | ||||||||||||||||||||
United States | ( | ( | ||||||||||||||||||
Non-United States | ||||||||||||||||||||
State and local | ( | ( | ||||||||||||||||||
Total deferred | ( | ( | ||||||||||||||||||
Provision for income taxes | $ | $ | $ |
Year Ended | ||||||||||||||||||||
December 31, 2024 | December 31, 2023 | December 31, 2022 | ||||||||||||||||||
Provision for income taxes at U.S. federal statutory income tax rate | $ | $ | $ | |||||||||||||||||
State and local income taxes, net of federal benefit | ||||||||||||||||||||
Net effects of foreign rate differential | ||||||||||||||||||||
Net effects of foreign operations | ||||||||||||||||||||
Nondeductible acquisition costs | ( | |||||||||||||||||||
Unrecognized tax benefits, net of federal benefit | ( | |||||||||||||||||||
Excess tax benefits related to equity compensation | ( | ( | ( | |||||||||||||||||
§162(m) compensation limitation | ||||||||||||||||||||
Nondeductible loss on divestiture of asbestos liabilities and certain assets | ||||||||||||||||||||
Net changes in valuation allowance | ( | ( | ||||||||||||||||||
Other | ( | ( | ( | |||||||||||||||||
Provision for income taxes | $ | $ | $ |
Year Ended | ||||||||||||||||||||
December 31, 2024 | December 31, 2023 | December 31, 2022 | ||||||||||||||||||
United States | $ | $ | $ | |||||||||||||||||
Non-United States | ||||||||||||||||||||
Income before income taxes | $ | $ | $ |
December 31, 2024 | December 31, 2023 | |||||||||||||
Deferred tax assets: | ||||||||||||||
Compensation and retirement benefits | $ | $ | ||||||||||||
General accruals and reserves | ||||||||||||||
Lease liabilities | ||||||||||||||
State tax net operating loss and credit carryforwards | ||||||||||||||
Federal and state capital loss carryforwards | ||||||||||||||
Foreign net operating loss carryforwards | ||||||||||||||
Other | ||||||||||||||
Total deferred tax assets before valuation allowance | ||||||||||||||
Valuation allowance | ( | ( | ||||||||||||
Total deferred tax assets | ||||||||||||||
Deferred tax liabilities: | ||||||||||||||
Property, plant and equipment | ||||||||||||||
Lease ROU assets | ||||||||||||||
Inventories | ||||||||||||||
Intangible assets and goodwill | ||||||||||||||
Total deferred tax liabilities | ||||||||||||||
Net deferred tax assets (liabilities) | $ | ( | $ | ( | ||||||||||
Net amount on Consolidated Balance Sheets consists of: | ||||||||||||||
Other assets | $ | $ | ||||||||||||
Deferred income taxes | ( | ( | ||||||||||||
Net long-term deferred tax assets (liabilities) | $ | ( | $ | ( |
Year Ended | ||||||||||||||
December 31, 2024 | December 31, 2023 | |||||||||||||
Balance at beginning of period | $ | $ | ||||||||||||
Additions based on tax positions related to the current year | ||||||||||||||
Additions for tax positions of prior years | ||||||||||||||
Reductions for tax positions of prior years | ( | |||||||||||||
Reductions due to lapse of applicable statute of limitations | ( | ( | ||||||||||||
Balance at end of period | $ | $ |
Year Ended | ||||||||||||||||||||
December 31, 2024 | December 31, 2023 | December 31, 2022 | ||||||||||||||||||
Net sales | $ | $ | $ | |||||||||||||||||
Less: | ||||||||||||||||||||
Cost of sales | ||||||||||||||||||||
Selling, general and administrative expenses | ||||||||||||||||||||
Other segment items (1) | ||||||||||||||||||||
Segment profit (Net income from continuing operations) | $ | $ | $ |
Net Sales | Long-lived Assets | ||||||||||||||||||||||||||||||||||
Year Ended December 31, 2024 | Year Ended December 31, 2023 | Year Ended December 31, 2022 | December 31, 2024 | December 31, 2023 | December 31, 2022 | ||||||||||||||||||||||||||||||
United States | $ | $ | $ | $ | $ | $ | |||||||||||||||||||||||||||||
Canada | |||||||||||||||||||||||||||||||||||
Rest of World | |||||||||||||||||||||||||||||||||||
$ | $ | $ | $ | $ | $ |
Plan category | Number of securities to be issued upon exercise of outstanding options, warrants and rights | Weighted-average exercise price of outstanding options, warrants and rights (2) | Number of securities remaining available for future issuance under equity compensation plans (excluding securities reflected in first column) | |||||||||||||||||
Equity compensation plans approved by security holders (1) | 2,885,144 | $18.72 | 963,928 | |||||||||||||||||
Equity compensation plans not approved by security holders | None | None | None | |||||||||||||||||
Total | 2,885,144 | $18.72 | 963,928 |
Additions | |||||||||||||||||||||||||||||
Description | Balance at Beginning of Year | Charged to Costs and Expenses | Charged to Other Accounts | Deductions (1) | Balance at End of Year | ||||||||||||||||||||||||
Year Ended December 31, 2022 | |||||||||||||||||||||||||||||
Valuation allowance for trade and notes receivable | ( | ||||||||||||||||||||||||||||
Valuation allowance for income taxes | ( | ||||||||||||||||||||||||||||
Year Ended December 31, 2023 | |||||||||||||||||||||||||||||
Valuation allowance for trade and notes receivable | ( | ||||||||||||||||||||||||||||
Valuation allowance for income taxes | ( | ||||||||||||||||||||||||||||
Year Ended December 31, 2024 | |||||||||||||||||||||||||||||
Valuation allowance for trade and notes receivable | ( | ( | |||||||||||||||||||||||||||
Valuation allowance for income taxes | ( |
Exhibit | Description | Incorporated Herein by Reference to | Filed Herewith | |||||||||||||||||
2.1 | Exhibit 99.2 to the Form 8-K filed by RBS Global, Inc./Rexnord LLC on May 19, 2005 | |||||||||||||||||||
2.2 | Exhibit 2.1 to the Company's Form 8-K filed February 19, 2021 | |||||||||||||||||||
2.3 | Exhibit 2.2 to the Company's Form 8-K filed February 19, 2021 | |||||||||||||||||||
2.4 | Exhibit 2.1 to the Company's Form 8-K filed February 14, 2022 | |||||||||||||||||||
3.1(a) | Exhibit 3.1 to the Company's Form 10-Q filed July 26, 2022 | |||||||||||||||||||
3.1(b) | Exhibit 3.1 to the Company's Form 8-K dated December 1, 2016 | |||||||||||||||||||
3.2 | Exhibit 3.2 to the Company's Form 8-K filed July 1, 2022 | |||||||||||||||||||
4.1 | Exhibit 4.1 to the Company's Form 10-K for the fiscal year ended December 31, 2023 | |||||||||||||||||||
10.1(a) | Exhibit 10.1 to the Form 8-K filed July 1, 2022 | |||||||||||||||||||
10.1(b) | Exhibit 10.3 to the Company's Form 8-K filed February 14, 2022 | |||||||||||||||||||
10.2 | Exhibit 10.3 to the Company’s Form 10-Q for the quarter ended June 30, 2020 | |||||||||||||||||||
10.3(a) | Exhibit 10.3 to the Company's Form 8-K filed July 1, 2022 | |||||||||||||||||||
10.3(b) | Appendix A to the Company’s Definitive Proxy Statement on Schedule 14A, filed on June 10, 2016 | |||||||||||||||||||
10.3(c) | Exhibit 10.32 to the Company's Registration Statement on Form S-1, SEC File No. 333-174504 | |||||||||||||||||||
10.3(d) | Exhibit 10.3(c) to the Company's Form 10-K for the fiscal year ended March 31, 2018 | |||||||||||||||||||
10.3(e) | Exhibit 10.2 to the Company's Form 10-Q for the quarter ended June 30, 2020 | |||||||||||||||||||
10.3(f) | Exhibit 10.3(d) to the Company's Form 10-K for the fiscal year ended March 31, 2018 | |||||||||||||||||||
10.3(g) | Exhibit 10.3(e) to the Company's Form 10-K for the fiscal year ended March 31, 2018 | |||||||||||||||||||
10.3(h) | Exhibit 10.4 to the Company's Form 10-Q for the quarter ended June 30, 2012 | |||||||||||||||||||
10.3(i) | Exhibit 10.2 to the Company's Form 10-Q for the quarter ended September 30, 2014 | |||||||||||||||||||
10.3(j) | Exhibit 10.6 to the Company’s 10-Q for the quarter ended June 30, 2016 | |||||||||||||||||||
10.3(k) | Exhibit 10.2 to the Company’s Form 10-Q for the quarter ended June 30, 2015 | |||||||||||||||||||
10.3(l) | Exhibit 10.3(f) to the Company’s Form 10-K for the fiscal year ended March 31, 2016 | |||||||||||||||||||
10.4 | Exhibit 10.1 to the Company's Form 8-K dated May 17, 2024 | |||||||||||||||||||
10.5 | Exhibit 10.3 to the Company’s Form 8-K dated May 18, 2016 (filed on May 24, 2016) | |||||||||||||||||||
10.6 | Exhibit 10.1 to the Company’s Form 10-Q for the quarter ended September 30, 2017 | |||||||||||||||||||
10.7 | Exhibit 10.8 to the Company’s Form 10-K for the fiscal year ended March 31, 2018 | |||||||||||||||||||
10.8 | Exhibit 10.2 to the Company’s Form 8-K dated December 13, 2018 | |||||||||||||||||||
10.9 | Exhibit 10.2 to the Company’s Form 10-Q for the quarter ended June 30, 2024 | |||||||||||||||||||
10.10 | Exhibit 10.3 to the Company's Form 10-Q for the quarter ended December 31, 2017 | |||||||||||||||||||
10.11(a) | Exhibit 10.2 to the Company's Form 8-K filed on October 5, 2021 | |||||||||||||||||||
10.11(b) | Exhibit 10.2 to the Company's Form 8-K filed July 1, 2022 | |||||||||||||||||||
10.12(a) | Exhibit 10.3 to the Company's Form 8-K filed on October 5, 2021 | |||||||||||||||||||
10.13(a) | Exhibit 10.1 to the Company's Form 8-K filed February 19, 2021 | |||||||||||||||||||
10.13(b) | Exhibit 10.2 to the Company's Form 8-K filed February 19, 2021 | |||||||||||||||||||
10.13(c) | Exhibit 10.3 to the Company's Form 8-K filed February 19, 2021 | |||||||||||||||||||
10.13(d) | Exhibit 10.4 to the Company's Form 8-K filed February 19, 2021 | |||||||||||||||||||
10.13(e) | Exhibit 10.1 to the Company's Form 8-K filed October 5, 2021 | |||||||||||||||||||
10.14 | Exhibit 10.17 to the Company's Annual Report on Form 10-K for the year ended December 31, 2022 | |||||||||||||||||||
10.15 | Exhibit 4.3 to the Company's Form S-8 filed May 3, 2024 | |||||||||||||||||||
19 | X | |||||||||||||||||||
21.1 | X | |||||||||||||||||||
23.1 | X | |||||||||||||||||||
24 | Signatures page hereto | |||||||||||||||||||
31.1 | X | |||||||||||||||||||
31.2 | X | |||||||||||||||||||
32.1 | X | |||||||||||||||||||
97 | Exhibit 97 to the Company's Annual Report on Form 10-K for the year ended December 31, 2023 | |||||||||||||||||||
101.INS | Inline XBRL Instance Document (The instance document does not appear in the interactive data file because its XBRL tags are embedded within the inline XBRL document.) | X | ||||||||||||||||||
101.SCH | Inline XBRL Taxonomy Extension Schema Document | X | ||||||||||||||||||
101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase Document | X | ||||||||||||||||||
101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase Document | X | ||||||||||||||||||
101.LAB | Inline XBRL Taxonomy Extension Label Linkbase Document | X | ||||||||||||||||||
101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase Document | X | ||||||||||||||||||
104 | Cover Page Inline XBRL data (contained in Exhibit 101) | X |
* | Denotes management plan or compensatory plan or arrangement. |
+ | The Company agrees to furnish supplementally a copy of the schedules omitted from this exhibit to the Commission upon request. |
ZURN ELKAY WATER SOLUTIONS CORPORATION | ||||||||
By: | /s/ Todd A. Adams | |||||||
Name: | Todd A. Adams | |||||||
Title: | Chairman of the Board and Chief Executive Officer | |||||||
Date: | February 10, 2025 |
/s/ Todd A. Adams | Chairman of the Board and Chief Executive Officer | February 10, 2025 | ||||||||||||
Todd A. Adams | (Principal Executive Officer) | |||||||||||||
/s/ David J. Pauli | Chief Financial Officer | February 10, 2025 | ||||||||||||
David J. Pauli | (Principal Financial and Accounting Officer) | |||||||||||||
/s/ Mark S. Bartlett | Director | February 10, 2025 | ||||||||||||
Mark S. Bartlett | ||||||||||||||
/s/ Jacques Don Butler | Director | February 10, 2025 | ||||||||||||
Jacques Don Butler | ||||||||||||||
/s/ Thomas D. Christopoul | Director | February 10, 2025 | ||||||||||||
Thomas D. Christopoul | ||||||||||||||
/s/ Timothy J. Jahnke | Director | February 10, 2025 | ||||||||||||
Timothy J. Jahnke | ||||||||||||||
/s/ David C. Longren | Director | February 10, 2025 | ||||||||||||
David C. Longren | ||||||||||||||
/s/ Emma McTague | Director | February 10, 2025 | ||||||||||||
Emma McTague | ||||||||||||||
/s/ George C. Moore | Director | February 10, 2025 | ||||||||||||
George C. Moore | ||||||||||||||
/s/ Rosemary Schooler | Director | February 10, 2025 | ||||||||||||
Rosemary Schooler | ||||||||||||||
/s/ Peggy N. Troy | Director | February 10, 2025 | ||||||||||||
Peggy N. Troy | ||||||||||||||